Highlights

• Botanix Pharmaceuticals shares rose 13.64% to AUD 0.025 during the morning session on 7 July 2026 after the company announced a favourable European patent update.

• The European Patent Office has issued an Intention to Grant for patent application EP 19799730.7.

• The patent covers proprietary applicator technology used with sofpironium topical gel, 12.45%, branded as Sofdra in the US.

• Following formal grant and validation in selected European countries, patent protection is expected to extend into May 2039.

• Botanix said the update may support potential ex-US commercialisation pathways in Europe, where Sofdra is not currently available.

Botanix Pharmaceuticals Ltd (ASX:BOT) shares climbed 13.64% to AUD 0.025 during the morning session on 7 July 2026 after the company announced that the European Patent Office had issued an Intention to Grant for a patent covering proprietary applicator technology linked to Sofdra. The update appears favourable for the company, as it strengthens intellectual property protection around the delivery and administration of its approved dermatology product. Despite today’s gain, Botanix shares remain down 91.94% over the past year.

Botanix Pharmaceuticals is a commercial dermatology company based in Philadelphia and Phoenix in the United States. The company has received FDA approval for Sofdra, its treatment for primary axillary hyperhidrosis, a medical condition involving excessive underarm sweating. Sofdra is described by Botanix as the first and only new chemical entity approved by the FDA for treating primary axillary hyperhidrosis. The company’s commercial focus is on dermatology treatments, with Sofdra forming a key part of its current product strategy.

European Patent Office Decision Supports Sofdra Applicator Protection

The latest update centres on European patent application EP 19799730.7, titled “Applicator and System for Pharmaceutical Preparation and Method of Use.”

Botanix said the European Patent Office has issued an Intention to Grant for the application, which covers proprietary applicator technology used with sofpironium topical gel, 12.45%. This product is branded as Sofdra in the United States.

The patent application relates to commercially relevant features of the applicator device used with the company’s topical gel product. These features are designed to support controlled topical administration and help patients use the product appropriately.

Following completion of the formal grant process and validation in selected European countries, the patent is expected to provide protection into May 2039.

For a pharmaceutical company, patent protection can be an important part of product positioning, particularly where the intellectual property covers not only the active product but also delivery-related technology. In Botanix’s case, the applicator forms part of the broader Sofdra product profile.

Applicator Technology Adds to Sofdra Product Profile

Botanix highlighted the applicator as an important part of Sofdra’s commercial and clinical use case.

The applicator is designed to help administer the topical gel while limiting unwanted contact between the drug and the hands. According to the company, physicians have identified this applicator feature as one of the reasons they prescribe Sofdra.

Chief Executive Officer Dr Howie McKibbon said the EPO decision further strengthens Botanix’s intellectual property estate around the delivery and administration of sofpironium topical gel. He also noted that the applicator technology is an important element of the Sofdra product profile.

The update therefore goes beyond a routine patent step. It relates to a component that Botanix sees as commercially relevant because it supports patient use and physician adoption.

Patent Protection Expected Into May 2039

Botanix said the patent, once formally granted and validated in selected European countries, is expected to provide protection into May 2039.

This timeline is notable because it gives the company a longer-term intellectual property pathway in Europe around its applicator technology. While Sofdra is currently not available in Europe, the company said the Intention to Grant is expected to enhance its value proposition for potential ex-US commercialisation pathways.

The wording is important: Botanix has not announced a European launch or commercial agreement in this update. Instead, the company has said the patent progress may support future commercialisation opportunities outside the United States.

This keeps the announcement focused on intellectual property protection and potential strategic value, rather than implying an immediate European market entry.

Sofdra Remains Central to Botanix’s Commercial Strategy

Sofdra is Botanix’s approved product for the treatment of primary axillary hyperhidrosis. The company describes the condition as socially challenging and notes that patients have lacked treatment options.

The product contains sofpironium topical gel, 12.45%, and has FDA approval in the United States.

For Botanix, Sofdra’s product profile includes not only the active drug formulation but also the delivery system used to apply it. The European patent update therefore strengthens an important part of the company’s broader Sofdra-related intellectual property position.

The company’s focus on the applicator also reflects the role of patient convenience and controlled administration in dermatology products, particularly those applied directly to the skin.

Potential European Pathway Remains a Watch Point

Botanix stated that the Intention to Grant is expected to enhance the company’s value proposition for potential ex-US commercialisation pathways in Europe.

This is relevant because Sofdra is not currently available in Europe.

The update does not include details of any European regulatory submission, commercial partner or launch timeline. However, additional patent protection may support future discussions or strategic planning related to the region.

Investors are likely to monitor whether Botanix provides further updates on international commercialisation, European market strategy or potential partnerships linked to Sofdra.

What This Means for Investors?

Botanix’s latest update appears positive because it strengthens the company’s intellectual property position around Sofdra’s applicator technology in Europe. The EPO’s Intention to Grant is not the final grant itself, but it signals progress toward formal patent protection. Once completed and validated in selected European countries, the patent is expected to protect the applicator technology into May 2039. For investors, the key point is that the update may support Botanix’s longer-term ex-US commercialisation options, although Sofdra is not currently available in Europe and no launch timeline was announced.